MedPath

SRH Wald-Klinikum Gera GmbH

🇩🇪Germany
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

4

Active:1
Completed:1

Trial Phases

4 Phases

Phase 1:1
Phase 2:1
Phase 4:1
+1 more phases

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials

Not Applicable
1 (25.0%)
Phase 1
1 (25.0%)
Phase 2
1 (25.0%)
Phase 4
1 (25.0%)

Surgical or Radiotherapeutic Intervention Concerning Large Singular Stable to Progressive Metastases in Patients With BRAFV600-mutated Melanoma Receiving Treatment With Encorafenib + Binimetinib

Not Applicable
Not yet recruiting
Conditions
Melanoma BRAF V600E/K Mutated
Interventions
First Posted Date
2025-07-29
Last Posted Date
2025-07-29
Lead Sponsor
SRH Wald-Klinikum Gera GmbH
Target Recruit Count
101
Registration Number
NCT07092410

Neoadjuvant Vismodegib in Patients With Large and/or Recurrent Resectable Basal Cell Carcinoma

Phase 2
Completed
Conditions
Basal Cell Carcinoma
Interventions
First Posted Date
2017-01-27
Last Posted Date
2022-02-11
Lead Sponsor
SRH Wald-Klinikum Gera GmbH
Target Recruit Count
40
Registration Number
NCT03035188
Locations
🇩🇪

SRH Wald-Klinikum Gera GmbH, Gera, Thuringia, Germany

🇩🇪

Klinikum Augsburg Süd, Augsburg, Germany

🇩🇪

Charité - Universitätsmedizin Berlin, Berlin, Germany

and more 9 locations

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.